๐ ๐๐๐๐๐๐๐๐ ๐๐๐๐ Goldman Sachs lifts global obesity-drug forecast to $114bn by 2030 as oral GLP-1s go mainstream - $Hims & Hers Health(HIMS.US) $Novo Nordisk AS(NVO.US) $Eli Lilly(LLY.US)
Goldman Sachs raised its forecast for the global obesity-drug market to $114bn by 2030, up roughly 13% from a $101bn projection in December, citing rapid adoption of oral GLP-1 obesity drugs and a shift from a niche, high-price segment to a mass-consumer market.The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments